StockNews.com assumed coverage on shares of NeuroMetrix (NASDAQ:NURO – Free Report) in a research report released on Friday morning. The brokerage issued a sell rating on the medical device company’s stock.
NeuroMetrix Stock Performance
NASDAQ:NURO opened at $3.71 on Friday. The stock has a fifty day moving average price of $4.04 and a 200-day moving average price of $3.71. The company has a market cap of $7.46 million, a price-to-earnings ratio of -0.59 and a beta of 2.16. NeuroMetrix has a fifty-two week low of $2.70 and a fifty-two week high of $8.30.
NeuroMetrix (NASDAQ:NURO – Get Free Report) last released its earnings results on Wednesday, May 15th. The medical device company reported ($1.67) earnings per share for the quarter. The company had revenue of $1.09 million for the quarter. NeuroMetrix had a negative net margin of 151.51% and a negative return on equity of 39.85%.
Institutional Trading of NeuroMetrix
NeuroMetrix Company Profile
NeuroMetrix, Inc, a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, and China. Its marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system offers services to device and provide disposable electrodes to a customer base of hand surgeons and manufacturers for industrial health use.
Featured Stories
- Five stocks we like better than NeuroMetrix
- High Flyers: 3 Natural Gas Stocks for March 2022
- Sarepta Therapeutics Stock Soars on FDA Approval
- Biggest Stock Losers – Today’s Biggest Percentage Decliners
- CarMax: A Market Melt-Up Waiting to Happen for this Stock
- Why Are Stock Sectors Important to Successful Investing?
- 3 Solar Stocks to Watch that are Building the Green Energy Future
Receive News & Ratings for NeuroMetrix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeuroMetrix and related companies with MarketBeat.com's FREE daily email newsletter.